

1 Evaluating metabolome-wide causal effects on risk for 2 psychiatric and neurodegenerative disorders

3 Lachlan Gilchrist^{1,2}, Julian Mutz¹, Pirro Hysi^{3,4,5}, Cristina Legido-Quigley^{6,7}, Sulev
4 Koks^{8,2}, Cathryn M. Lewis^{1,9,*} and Petroula Proitsi^{10,11,*}

5
6 ¹ Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
7 Neuroscience, King's College London, London, United Kingdom

8 ² Perron Institute for Neurological and Translational Science, Perth, Australia

9 ³ Department of Ophthalmology, King's College London, London, UK

10 ⁴ Department of Twins Research and Genetic Epidemiology, King's College London, London, UK

11 ⁵ Sørlandet Sykehus Arendal, Arendal, Norway

12 ⁶ Systems Medicine, Institute of Pharmaceutical Science, Life Science & Medicine, King's College
13 London, London, UK

14 ⁷ Steno Diabetes Center Copenhagen, Copenhagen, Denmark

15 ⁸ Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia

16 ⁹ Department of Medical and Molecular Genetics, King's College London, London, United Kingdom

17 ¹⁰ Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary's University of
18 London

19 ¹¹ Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology, and
20 Neuroscience, King's College London, London, United Kingdom

21
22 * equally contributing authors/co-corresponding authors: Dr. Petroula Proitsi
23 (p.proitsi@qmul.ac.uk) and Prof. Cathryn Lewis (cathryn.lewis@kcl.ac.uk)

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41

Abstract

42 Evidence indicates phenotypic and biological overlap between psychiatric and
43 neurodegenerative disorders. Further identification of underlying mutual and unique biological
44 mechanisms may yield novel multi-disorder and disorder-specific therapeutic targets. The
45 metabolome represents an important domain for target identification as metabolites play
46 critical roles in modulating a diverse range of biological processes. Here, we used Mendelian
47 randomisation (MR) to test the causal effects of ~1000 plasma metabolites and ~300
48 metabolite ratios on anxiety, bipolar disorder, depression, schizophrenia, amyotrophic lateral
49 sclerosis, Alzheimer's disease, Parkinson's disease and multiple sclerosis. In total, 85 causal
50 effects involving 77 unique metabolites passed FDR correction and robust sensitivity analyses
51 (IVW-MR OR range: 0.73-1.48; $p_{FDR} < 0.05$). No evidence of reverse causality was identified.
52 Multivariate analyses implicated sphingolipid metabolism in psychiatric disorder risk and
53 carnitine derivatives in risk for amyotrophic lateral sclerosis and multiple sclerosis. However,
54 polygenic risk scores for prioritised metabolites showed limited prediction in the UK Biobank.
55 Downstream colocalisation in regions containing influential variants identified greater than
56 suggestive evidence ($PP.H_4 \geq 0.6$) for a shared causal variant for 29 metabolite/psychiatric
57 disorder trait-pairs on chromosome 11 at the *FADS* gene cluster. Most of these metabolites
58 were lipids containing linoleic or arachidonic acid. Additional colocalisation was identified
59 between the ratio of histidine-to-glutamine, glutamine, Alzheimer's disease and *SPRYD4* gene
60 expression on chromosome 12. Although no single metabolite had a causal effect on a
61 psychiatric and a neurodegenerative disease, results suggest a broad effect of lipids across
62 brain disorders. Metabolites identified here may help inform future targeted interventions.

63 1. Introduction

64 Psychiatric disorders show substantial co-morbidity¹ and shared genetic
65 architecture². Additionally, they are common both prior to and within
66 neurodegenerative diseases³⁻⁷ – themselves genetically related^{8,9} – and are indicated
67 as risk factors for their later onset¹⁰⁻¹². Genomic analyses suggest that psychiatric and
68 neurodegenerative risk are partially underpinned by shared risk loci and causal brain
69 transcripts and proteins¹³⁻¹⁷. By further investigating shared biological risk
70 mechanisms, novel interventions may be identified with effectiveness for specific or
71 multiple disorders.

72 Metabolomics – the study of small molecules linked to metabolism – is a
73 promising tool for such investigation as it represents the stage of the omics cascade
74 closest to the phenotype¹⁸. Importantly, metabolites are strong drug target
75 candidates as many are obtained dietarily and modulate diverse biological
76 processes including gene expression, RNA metabolism and protein activity¹⁹⁻²¹.
77 Obtaining samples is minimally invasive as thousands of metabolites can be detected
78 in plasma, serum or urine²².


79 Similar metabolite groups, such as ceramides, are indicated to play a role in
80 both psychiatric and neurodegenerative disorders²³⁻²⁷. However, observational
81 studies may be confounded by reverse causation²⁸. Importantly for psychiatric and
82 neurodegenerative disorders, the metabolome can be perturbed by disease
83 pathology and/or pharmaceutical interventions²⁹⁻³³. As such, following onset and
84 treatment discerning the direction of effect and identifying causal metabolite targets
85 is challenging. These limitations can be addressed using Mendelian randomisation
86 (MR), a statistical framework that leverages genetic variants as instrumental variables
87 (IVs) to proxy an exposure and infer its causal effect on an outcome of interest³⁴. As
88 risk alleles are randomly assorted and fixed from conception, MR is less vulnerable
89 to reverse causality than classical epidemiological approaches^{28,35}. Beneficially, this
90 approach can be performed using summary statistics from large genome-wide
91 association studies (GWAS) (two-sample MR (2SMR)), allowing researchers to
92 perform increasingly powerful analyses³⁶. This approach applied to the metabolome
93 has already identified several causal risk metabolites for Alzheimer's disease, bipolar
94 disorder, major depressive disorder, and multiple sclerosis³⁷⁻⁴¹.

95 However, no study has yet been conducted to identify shared and unique
96 metabolomic risk factors across the psychiatric and neurodegenerative disorder
97 spectrum. In this study, we assess the causal effect of ~1000 unique plasma
98 metabolites and ~300 metabolite ratios on four psychiatric disorders (anxiety, bipolar
99 disorder, depression and schizophrenia) and four neurodegenerative diseases
100 (amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease

101 (PD) and multiple sclerosis (MS)). We further prioritise key metabolites using
102 Bayesian model averaging, identify regions of shared causal variants with statistical
103 colocalisation – integrating expression quantitative trait loci (eQTLs) – and assess the
104 predictive performance of polygenic scores for risk metabolites on incident diseases
105 in the UK Biobank (UKB).

106 **2. Methods**

107 An overview of the analyses is shown in Figure 1.



108

109 *Figure 1: Analysis flowchart. In the Mendelian randomisation section, the three key assumptions are*
110 *illustrated and can be described as: (1) Instruments must be robustly associated with the exposure –*
111 *usually defined as genome-wide statistical significance of the variants; (2) Instruments are not*
112 *associated with a confounder and (3) Instruments are not associated with the outcome via pathways*
113 *other than through the exposure, for example through horizontal pleiotropy. These assumptions are*
114 *known as the (1) relevance, (2) independence and (3) exclusion restriction assumption, respectively.*
115 *ANX = anxiety; ALS = amyotrophic lateral sclerosis; AD = Alzheimer's disease; BP = bipolar disorder;*
116 *DEP = depression; MS = multiple sclerosis; PD = Parkinson's disease; SCZ = schizophrenia*

117

118 2.1 GWAS summary statistics

119 2.1.1 Neuropsychiatric disorders

120 An overview of the GWAS summary statistics is shown in **Table 1**. These consisted of
121 individuals of European ancestry only. For each disorder, we performed inverse
122 variance weighted (IVW) genome-wide meta-analysis across samples^{9,42–51} using
123 METAL⁵² to maximise sample size and statistical power. Details on each sample can
124 been seen in the original papers. For AD, we used summary statistics that did not
125 contain family history-based proxy phenotyping from the UK Biobank given its noted
126 influence on the effect direction of downstream analyses⁵³. The *APOE* region
127 (chr19:45,020,859–45,844,508 (GRCh37)) was excluded from the AD GWAS due to
128 known pleiotropic effects on relevant non-AD diseases such as heart disease and
129 hypercholesterolaemia⁵⁴. It was not meta-analysed with FinnGen freeze 9 as with the
130 others as the sample already contained samples from a previous FinnGen freeze.
131 Genetic correlations between these disorders – calculated using Linkage
132 Disequilibrium Score Regression (LDSC)⁵⁵ in GenomicSEM⁵⁶ v.0.0.5 – are described
133 and plotted in **Supplementary Material 1** and **2**, respectively. Full output tables are
134 in **Supplementary Tables 1** and **2**. Effective sample sizes were calculated as per
135 Grotzinger et al.⁵⁷, providing comparable sample size estimates representing
136 equivalently powered GWAS with a 1:1 case/control ratio.

Category	Phenotype	GWAS sample	N Cases	N Controls	Total cases	Total controls	N_{eff}
Psychiatric	Anxiety	Purves et al.	25,453	58,113	70,228	354,864	226,035
		Meier et al. (IPSYCHE)	4,584	19,225			
		Finngen Freeze 9 (KRA_PSY_ANXIETY)	40,191	277,526			
	Bipolar disorder	Mullins et al.	41,917	371,549	48,923	651,818	129,398
		Finngen freeze 9 (F5_BIPO)	7,006	329,192			
	Depression	Million Veterans Project	83,810	166,405	298,038	824,848	825,105
		Psychiatric Genomics Consortium/UK Biobank (Howard et al.)	170,756	329,443			
		Finngen freeze 9 (F5_DEPRESSIO)	43,280	329,192			
	Schizophrenia	Trubetskoy et al.	53,386	77,258	66,447	354,784	176,178
Finngen freeze 9 (KRA_PSY_SCHIZODEL)		13,061	277,526				
Neurodegenerative	Alzheimer's disease				39,918	358,140	89,308
		Wightman et al. (excl. UKB)	39,918	358,140			
	Amyotrophic lateral sclerosis	van Rheenen et al.	27,205	110,881	27,686	281,548	115,084
		Finngen freeze 9 (G6_ALS)	483	170,667			
	Multiple Sclerosis	International Multiple Sclerosis Consortium	47,429	68,374	49,611	442,361	120,692
		Finngen freeze 9	2,182	373,987			
	Parkinson's disease	Nalls et al.	33,674	449,056	37,441	822,098	120,692
Finngen freeze 9		4,235	373,042				

138 *Table 1: Previously conducted genome-wide association study summary statistics for psychiatric and*
139 *neurodegenerative disorders used in this study.*

140

141 2.1.2 Plasma metabolites

142 We obtained metabolite summary statistics from two studies conducted in non-
143 overlapping samples: (1) 1,091 individual metabolites and 309 metabolite ratios
144 measured in 8,299 unrelated individuals from the Canadian Longitudinal Study of
145 Aging (CLSA)⁵⁸ and (2) 722 individual metabolites measured in 8,809 individuals in
146 the NIHR UK Bioresource cohort⁵⁹. In both studies, metabolites were detected and
147 quantified in plasma by Metabolon Inc. using ultra-high performance liquid
148 chromatography-tandem mass spectroscopy. Unidentified metabolites were
149 excluded from analyses. We performed genome-wide meta-analysis as above for 431
150 metabolites when the same metabolite was available in both samples for a meta-
151 analysed sample size of 17,038.

152

153 2.1.3 GWAS standardisation

154 Prior to meta-analysis, summary statistics were standardised with MungeSumstats⁶⁰
155 version in R (v.4.2.1) using dbsnp 144 and the
156 BSgenome.Hsapiens.1000genomes.hs37d5 reference genome available through
157 Bioconductor (v.3.1.3). Missing rsids were obtained, duplicate and multi-allelic

158 variants excluded, and alleles aligned to the reference, flipping effect and frequency
159 direction accordingly. Where necessary, MungeSumstats was used to lift over
160 genome build coordinates from GRCh38 to GRCh37 via the UCSC Genome Browser
161 chain file.

162

163 2.2 Mendelian randomisation

164 2.2.1. Metabolite instrument selection

165 Independent instrumental variables (IVs) were initially selected at genome-wide
166 significance ($p \leq 5 \times 10^{-8}$), clumping at an r^2 threshold of 0.001 within 10,000 kb of the
167 lead variants. Clumping was conducted using the ieugwasr package (v.0.1.4), PLINK
168 (v.1.9)⁶¹ binaries and the European sample of the 1000 Genomes phase 3 reference
169 panel⁶² ($N = 503$), restricted to minor allele frequency (MAF) > 0.01 . This is the same
170 reference panel used by the MRC IEU OpenGWAS database⁶³
171 (<http://files.mrcieu.ac.uk/ld/1kg.v3.tgz>).

172 Where less than five IVs were available for any given exposure, a lower p -value
173 threshold of 5×10^{-6} was used for IV selection as per previous analyses⁶⁴. If less than
174 5 IVs were available at the 5×10^{-6} threshold, this metabolite was excluded. Where an
175 IV was not available for the outcome, proxy IVs (i.e., variants in linkage disequilibrium
176 (LD) with the original instrument at $r^2 > 0.8$) were identified using snappy (v.1.0)
177 (<https://gitlab.com/richards-lab/vince.forgetta/snappy>) and same reference panel.
178 Proxies were selected using the highest r^2 value and closest genomic position. Prior
179 to analysis, exposure and outcome were harmonised to the same effect allele, and
180 strand ambiguous palindromic variants (MAF > 0.42) dropped. Instrument strength
181 was assessed via their F-statistic ($\beta_{\text{exposure}}^2 / \text{SE}_{\text{exposure}}^2$), with weak instruments (F-
182 statistic < 10) excluded. If less than 5 IVs remained, the metabolite was again
183 excluded. Instrument measurement error was assessed with the I^2_{G-X} statistic (< 0.9
184 suggestive of measurement error)⁶⁵.

185 Following the above steps the effects of 428 meta-analysed metabolites were
186 tested, plus 740 and 132 metabolites from the CLSA and NIHR UK Bioresource
187 studies, respectively, for a total of 1300 unique metabolites/metabolite ratios.

188

189 2.2.2. MR analyses

190 We conducted the primary analyses using inverse variance weighted MR (IVW-
191 MR) with multiplicative random effects as recommended⁶⁶. If the IVW-MR estimate
192 was statistically significant after Benjamini-Hochberg false discovery rate (FDR)
193 correction⁶⁷ ($p_{FDR} \leq 0.05$, corrected for total number of tests *specific to each* outcome),
194 six sensitivity analyses were conducted to assess its robustness to violations of the
195 pleiotropy assumption and instrument validity. We implemented methods that assume

196 a majority valid instruments (weighted median⁶⁸; penalised weighted median⁶⁹),
197 plurality valid instruments (constrained maximum likelihood (cML)⁷⁰; contamination
198 mixture model MR (MR-ContMix)⁷¹), and that exclude invalid outliers (MR-Lasso⁷²).
199 Additionally, we used MR-Egger⁷³, which gives consistent causal estimates even if all
200 instruments are not valid, provided pleiotropic effects are not correlated with variant-
201 exposure associations. This is known as the Instrument Strength Independent of
202 Direct Effect (InSIDE) assumption and is MR-Egger-specific. To pass sensitivity
203 criteria, all sensitivity analysis point estimates needed to be directionally concordant
204 with the IVW estimate and the majority (≥ 4) statistically significant at $p \leq 0.05$. Where
205 a metabolite passed sensitivity criteria, we performed reverse IVW-MR as above with
206 the outcome as the exposure.

207 Pleiotropy was assessed using the MR-Egger intercept test (no evidence of
208 pleiotropy: $p_{Egger-Intercept} \geq 0.05$) and heterogeneity using Cochran's Q (no evidence of
209 heterogeneity: $p_{Q-Stat} \geq 0.05$). Metabolites passing sensitivity were further inspected
210 using leave-one-out (LOO) analysis to assess whether causal estimates were driven
211 by the inclusion of a single influential variant. Metabolites that passed sensitivity
212 criteria and had no LOO outlier variant were considered polygenic metabolites and
213 are referred to as such henceforth. Those passing sensitivity but with a LOO outlier
214 variant were considered single instrument metabolites.

215

216 **2.2 Further analysis of polygenic metabolites**

217 **2.3.1 Conditional analysis**

218 Hysi et al.⁵⁹ noted that many metabolites are genetically correlated with phenotypes
219 related to body composition and educational level. To assess whether any identified
220 effects were driven in part by the genetic correlations between the metabolites and
221 these phenotypes, we performed conditional GWAS of the neuropsychiatric disorders
222 using multi-trait conditional and joint analysis (mtCOJO)⁷⁴ to remove the per-SNP
223 effects of body mass index (BMI), BMI-adjusted waist-to-hip ratio (WHR), and
224 educational attainment (EA).

225 We obtained GWAS summary statistics for BMI ($N = 806,834$) and BMI-
226 adjusted waist-to-hip ratio ($N = 697,734$) from the GIANT consortium^{75,76}. We
227 additionally obtained summary statistics for educational attainment (EA) from the EA4
228 GWAS meta-analysis, excluding 23andMe, from the Social Science Genetic
229 Association Consortium (SSGAC)⁷⁷ ($N = 765,283$).

230 IVW-MR estimates were recalculated for significant metabolite-
231 neuropsychiatric disorder pairs post-mtCOJO and compared to the original
232 estimates. Forest plots were visually inspected for evidence of attenuation between
233 original and adjusted estimates.

234

235 **2.3.2 Metabolite prioritisation using MR-BMA**

236 Metabolites are highly genetically correlated⁵⁸. Consequently, univariate MR
237 estimates – which assume exposures are independent – may be biased by the
238 pleiotropic effects of other risk metabolites. Such issues may be addressed using MR
239 with Bayesian model averaging (MR-BMA)⁷⁸. MR-BMA is a multivariable MR
240 approach that ranks of causal effects among related exposures according to their
241 independent causal signal. Unlike conventional multivariable MR methods, MR-BMA
242 is well suited for the highly correlated nature of high-throughput exposures such as
243 metabolites⁷⁸. Instruments were selected by pooling those used in IVW-MR for all per-
244 disorder statistically significant metabolites, excluding correlated instruments as
245 before ($r^2 > 0.001$, window = 10,000 kb). We use a prior probability of 0.1 and a prior
246 variance of 0.25 as previously^{78,79}. Metabolites were ranked according to their
247 marginal posterior probability (MIP), with $MIP \geq 0.1$ interpreted as causal. To avoid
248 multicollinearity between the exposures, we calculated a genetic correlation matrix
249 using the linkage disequilibrium score regression (LDSC)⁸⁰ function of
250 GenomicSEM⁵⁶. As per the original MR-BMA study, where point estimates ≥ 0.95 , we
251 excluded the metabolite correlated with the most other metabolites (if $> one$) or
252 retained only the metabolite with the most-significant IVW-MR estimate in the MR-
253 BMA analysis (if only one).

254

255 **2.3.2 Cross-trait polygenic score (PGS) analysis**

256 To assess whether any of the polygenic metabolites prioritised in MR-BMA be used
257 for disease prediction, we calculated polygenic scores (PGS) – the weighted sum of
258 an individual's risk alleles⁸¹ – within the reference standardised framework of the
259 GenoPred pipeline⁸² using individual level data from the UK Biobank (UKB)⁸³. Within
260 GenoPred, allele weights were calculated using MegaPRS⁸⁴, a PGS method that uses
261 the BLD-LDAK heritability model and improves prediction by incorporating
262 information on allele frequency, LD and various functional annotations. MegaPRS has
263 shown strong predictive performance compared to other PGS methods^{85,86}.

264 UKB participants were excluded from analyses if they had unusual levels of
265 heterozygosity, a call missing rate $>2\%$ or discordant phenotypic and genetic sex (F_x
266 < 0.9 for males, $F_x > 0.5$ for females). Individuals were filtered for relatedness up to
267 3rd degree relatives based on KING kinship estimates ($r < 0.044$)⁸⁷ using
268 GreedyRelate (v1.2.1) to remove one individual from each related pair, maximising
269 sample size (<https://gitlab.com/choishingwan/GreedyRelated>). Analyses were
270 restricted to individuals of European ancestry. The final sample contained 381,564
271 individuals prior to any age-based exclusions.

272 Case/control status was defined using the first occurrence data fields from the
273 UKB (**Supplementary Table 3**), where cases were ascertained using primary care
274 Read v2 or Read CTV3 codes, hospital inpatient ICD-9 and ICD-10 codes, death
275 record ICD-10 codes and medical condition codes self-reported at UKB assessment
276 centre visits. Individuals were excluded if the code had no event date or if the date
277 of event was before, the same year as or on the participants date of birth, or a date
278 in the future. Associations between metabolite-PGS and respective neuropsychiatric
279 disease was assessed using logistic regression, controlling for age, sex, genotyping
280 batch, assessment centre and the first ten genetic principal components from the
281 UKB. Within each model, the comparison group was restricted to individuals with no
282 occurrence of any of the neuropsychiatric disorders. To provide age-appropriate
283 controls for AD and PD, samples were restricted for those analyses to individuals
284 aged ≥ 60 and ≥ 50 years, respectively. For DEP and ANX cases, individuals with an
285 occurrence of BP or SCZ were excluded. The variance explained by each PGS was
286 assessed using Nagelkerke's pseudo- r^2 . Sample sizes ranged from 140,154 to
287 356,763, depending on the disorder, with case numbers ranging from 600 (ALS) to
288 46,900 (DEP) (mean age range = 56.65-64.13; %male range = 46.32-49.35).

289

290 **2.4 Further analysis of single instrument metabolites**

291 **2.4.1 Statistical colocalisation**

292 Using LOO analysis, we identified IVs that significantly attenuated the IVW-MR
293 estimate when excluded. We extracted regions ± 250 kb of these IVs and performed
294 statistical colocalisation for each metabolite and the respective neuropsychiatric
295 disorder within the COLOC-reporter pipeline⁸⁸. Regions of interest were extracted and
296 harmonised for each phenotype to contain only shared variants on the reference
297 panel. Colocalisation was performed using the *coloc.abf* function of the COLOC
298 package⁸⁹. A posterior probability of 0.8 for hypothesis four (PP.H₄) – presence of a
299 shared causal variant between the phenotypes – was taken as evidence of
300 colocalisation (PP.H₄ ≥ 0.6 taken as suggestive).

301

302 **2.4.2 eQTL colocalisation**

303 For regions of colocalisation (including suggestive), we identified genes located
304 within 10 kb of credible SNPs using Ensembl and biomaRt (v.2.54.0). For each gene,
305 we extracted *cis*-eQTLs from the whole blood eQTL summary data of the eQTLGen
306 Consortium⁹⁰ ($N = 31,684$) and performed colocalisation between the eQTLs and both
307 phenotypes in each metabolite-neuropsychiatric disorder pair as above.

308

309

310 2.4.2 eQTL MR

311 For genes colocalising with both the metabolite and neuropsychiatric disorder a trait-
312 pair, we extracted independent instruments for gene expression from the eQTL
313 summary statistics ($p \leq 5 \times 10^{-8}$; $r^2 \leq 0.001$; window = 10,000 kb) and used IVW-MR
314 to assess the causal effect of gene expression levels on the outcome and exposure.
315 We examined the consistency of the gene expression causal effects using Summary-
316 based Mendelian Randomisation (SMR)⁹¹, extracting eQTL probes for the relevant
317 gene from blood-based eQTL summary datasets from Westra et al.⁹² ($N = 3,511$) and
318 Lloyd-Jones et al.⁹³ ($N = 2,765$). Heterogeneity was assessed using the
319 HEterogeneity In Dependent Instruments (HEIDI) test, with $p_{\text{HEIDI}} < 0.05$ indicative of
320 heterogeneity. This is essentially a test of colocalisation.

321 Previous research has indicated that the causal effect of gene expression on
322 a complex trait can be mediated by the effect of metabolites within a transcript-
323 metabolite-trait causal triplet⁹⁴. Where gene expression levels showed a significant
324 causal effect on both an outcome and a metabolite, we calculated the proportion
325 mediated using the product of coefficients method as per previous analyses⁹⁵.
326 Standard errors were estimated using the delta method and p -values drawn from a
327 z-score distribution.

328

329 3. Results

330 3.1 Mendelian randomisation

331 We conducted a total of 10,327 tests of the causal effect of the metabolites and ratios
332 on the eight neuropsychiatric outcomes (instrument N -range: 5-27). Of these, 1695
333 tests were conducted with instruments clumped at 5×10^{-8} and 8632 with instruments
334 clumped at 5×10^{-6} . For single instruments, F-statistics ranged from 10.11 to 5625.88
335 (mean per-test F-statistics range: 20.77-1163.90). Analyses were thus not impacted
336 by weak instruments. Per-test I^2_{G-X} ranged from 0.45 to 1.000. Only 94 tests (0.009%),
337 involving 13 unique metabolites, were conducted with $I^2_{G-X} < 0.9$, suggestive of
338 measurement error. Only 27 tests were conducted using instruments with $I^2_{G-X} \leq 0.8$,
339 involving six metabolites: 2-hydroxyarachidate, 4-hydroxy-2-oxoglutaric acid, 4-
340 vinylguaiacol sulphate, glycolithocholate, and O-cresol sulphate.


341 Primary IVW-MR analyses identified 138 causal effects involving 113 unique
342 metabolites after outcome-specific FDR correction (**Supplementary Table 4; Figure**
343 **2a**). Of these, 85 metabolite-outcome pairs passed our sensitivity criteria, involving
344 77 unique metabolites (**Supplementary Table 5**). All neuropsychiatric disorders had
345 two or more metabolites with statistically significant effects. No reverse effects were
346 detected for these metabolite-outcome pairs after FDR-correction (**Supplementary**
347 **Table 6**). IVW-MR odds ratios (OR) for metabolite-neuropsychiatric disorder trait-

348 pairs ranged from 0.73 to 1.48 (p -value range: 1.52×10^{-3} - 9.67×10^{-31} ; p_{FDR} range:
349 4.45×10^{-2} - 1.26×10^{-27}). However, MR-Egger intercept tests detected significant
350 pleiotropy for eight of the 85 metabolite-outcome pairs ($p_{Egger-Intercept} < 0.05$)
351 (**Supplementary Table 7**). Cochran's Q heterogeneity tests detected significant
352 heterogeneity for 15 ($p_{Q-Stat} < 0.05$) (**Supplementary Table 8**). All metabolite-outcome
353 pairs with $p_{Egger-Intercept} < 0.05$ and 14 out of 15 with $p_{Q-Stat} < 0.05$ were identified as
354 influenced by single influential variants in the LOO analysis (**Supplementary Table**
355 **9**). Only the effect of the ratio of mannose to glycerol on depression ($p_{Q-Stat} = 0.043$)
356 was not driven by a single influential variant.

357 Excluding metabolites with effect estimates primarily influenced by single
358 variants left a total of 41 metabolite-neuropsychiatric disorder trait-pairs with
359 polygenic metabolites – all unique. Of these, 13 were identified with depression,
360 seven with MS, six with ALS, four each with AD and bipolar disorder, three with
361 schizophrenia, and two each with anxiety and PD (**Figure 2b**). These metabolites
362 were linked to nine broad metabolic classes (super-pathways), counting the
363 combinations of pathways of metabolite ratios as unique pathways (**Figure 2b**;
364 **Supplementary Table 10**). Over half ($N = 22$) were lipids, and the rest amino acids
365 ($N = 10$), nucleotides ($N = 3$), peptides ($N = 1$), carbohydrates ($N = 1$) or ratios
366 involving amino acid/cofactors and vitamins ($N = 1$), amino acid/energy ($N = 1$) and
367 carbohydrate/lipid ($N = 1$) pathways. The remaining metabolite – glutamine conjugate
368 of C6H10O2 (2) – is considered only partially characterised.

369 These metabolites were implicated in 28 unique sub-pathways representing
370 the metabolic/biochemical subclasses related to the metabolites (**Figure 2c**;
371 **Supplementary Table 10**). The largest group of metabolites was related to
372 sphingolipid metabolism ($N = 5$). All metabolites involved in sphingolipid metabolism
373 had effects on psychiatric disorder risk. Sphingosine 1-phosphate has a risk
374 increasing effect on bipolar disorder (OR [95%CI] = 1.17 [1.06-1.28], p -value = 9.49
375 $\times 10^{-4}$, $p_{FDR} = 0.03$), while glycosyl-N-stearoyl-sphingosine (d18:1/18:0),
376 sphingomyelin (d18:1/24:1, d18:2/24:0) and sphingomyelin (d18:2/23:0, d18:1/23:1
377 and d17:1/24:1) has risk decreasing effects on depression (OR range: 0.93-0.96, p -
378 value range: 2.38×10^{-4} – 9.91×10^{-4} ; p_{FDR} range: 0.02-0.04). Additionally,
379 sphingomyelin (d18:1/18:1, d18:2/18:0) has a risk decreasing effect on schizophrenia
380 (OR [95%CI] = 0.87 [0.81-0.94], p -value = 1.89×10^{-4} , $p_{FDR} = 0.04$).

381



383

384

385 *Figure 2: (a). Volcano plots for anxiety (ANX), bipolar disorder (BP), depression (DEP), schizophrenia*
 386 *(SCZ), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and*
 387 *Parkinson's disease (PD) showing odds ratios and $-\log_{10}$ p-values from inverse variance weighted*
 388 *Mendelian randomisation (IVW-MR) for all tested metabolites. (b). Forest plot of FDR statistically*
 389 *significant metabolites associated with neuropsychiatric outcomes in IVW-MR and passing sensitivity*
 390 *tests, with no leave-one-out (LOO) outliers (i.e., polygenic metabolites). Point estimates indicate odds*
 391 *ratios with bars representing 95% confidence intervals (95%CI). Point estimates for each metabolite*
 392 *are coloured according to their metabolic super-pathway. (c). Stacked histograms showing total count*
 393 *of FDR statistically significant polygenic metabolites associated with each neuropsychiatric disorder,*
 394 *with fill colours indicating metabolite sub-pathways. AD = Alzheimer's disease; ALS = Amyotrophic*
 395 *Lateral Sclerosis; ANX = anxiety; BP = Bipolar Disorder; DEP = Depression; MS = Multiple Sclerosis;*
 396 *PD = Parkinson's disease; SCZ = Schizophrenia*

397

398 The strongest negative effect was observed for the amino acid leucine and PD
 399 (OR [95%CI] = 0.73 [0.62-0.85], $p = 9.64 \times 10^{-5}$; $p_{FDR} = 3.13 \times 10^{-2}$). Isoleucine showed
 400 similar effects (OR = 0.73 [0.62-0.86]; $p = 1.65 \times 10^{-4}$; $p_{FDR} = 4.28 \times 10^{-2}$). The strongest
 401 positive effect was observed for the lipid 1-(1-enyl-oleoyl)-GPE (P-18:1) and MS (OR


402 = 1.48 [1.33-1.65]; p -value = 2.71×10^{-12} ; $p_{FDR} = 3.42 \times 10^{-9}$). The most statistically
403 significant effect was identified for the ratio of arachidonate (20:4n6) to oleate to
404 vaccenate (18:1) and anxiety (OR = 0.93 [0.93-0.95], p -value = 9.67×10^{-31} , $p_{FDR} =$
405 1.26×10^{-27}).

406 The remaining 44 metabolite-neuropsychiatric disorder trait-pairs had
407 attenuated effects in the LOO analysis, involving 36 unique metabolites and six of the
408 neuropsychiatric outcomes (**Supplementary Table 11**). Most of the effects were
409 observed in relation to psychiatric disorders ($N = 40$), primarily with BP ($N = 16$) and
410 DEP ($N = 16$). Another four were observed with ANX and three with SCZ. These
411 metabolite-psychiatric trait-pairs involved 33 unique metabolites, 25 of which were
412 lipids and one a ratio of lipid/carbohydrate. These lipids were involved in 12 unique
413 sub-pathways, the largest group of which was related to phospholipid metabolism (N
414 = 6). The remainder were amino acids ($N = 5$), a carbohydrate ($N = 1$) and a
415 xenobiotic ($N = 1$), involved in seven unique sub-pathways. Of those remaining, four
416 unique single instrument metabolites had a causal effect AD – two amino acids and
417 two xenobiotics – and a nucleotide showed causal effect on MS.

418 A total of 31 of the LOO associations were driven by 11 influential variants on
419 chromosome 11 within a ~500 kb window (61293499-61854782 bp). This region
420 contains the fatty acid desaturase (*FADS*) gene cluster, which is linked to the
421 regulation of fatty acid levels and their circulation⁹⁶. All metabolites influenced by
422 these variants were lipids and associated with psychiatric disorder risk ($N_{ANX} = 4$, N_{BP}
423 = 13, $N_{DEP} = 12$ and $N_{SCZ} = 2$). Between-variant LD estimates for the influential
424 instruments in this region were calculated using LDlinkR (v.1.3)⁹⁷ and ranged from
425 0.16-1, with $r^2 \geq 0.72$ for all variants except rs14570 and rs2524299 which showed a
426 maximum r^2 of 0.34 and 0.38, respectively (**Figure 3a; Supplementary Table 12**).

427 We used Wald ratio tests to re-estimate the effect of single instrument
428 metabolites on the relevant outcome using the influential instrument only. F-statistics
429 ranged from 105.37 to 5625.88. Wald estimates were directionally consistent with
430 IVW-MR estimates and remained significant at $p \leq 0.05$, although the protective
431 effects of 4-guanidinobutanoate and mannonate on AD were only nominally
432 significant ($p = 0.04$ and 0.02 , respectively) (**Figure 3b; Supplementary Table 13**).
433 Regions containing influential instruments were further investigated using
434 colocalisation.

435



436

437 *Figure 3: (a). The r^2 estimates between influential single variants on chromosome 11 alongside their*
 438 *genomic location. (b). Recalculated Wald ratio estimates for metabolites with influential single variants*
 439 *using the influential variant only. Point estimates indicate odds ratios with bars representing 95%*
 440 *confidence intervals (95%CI). Point estimates for each metabolite are coloured according to their*
 441 *metabolic super-pathway. AD = Alzheimer's disease; ANX = anxiety; BP = Bipolar Disorder; DEP =*
 442 *Depression; MS = Multiple Sclerosis; SCZ = Schizophrenia*

443

444 3.2 Further analysis of polygenic metabolites

445 3.2.1 Conditional analysis

446 Conditioning neuropsychiatric outcomes on BMI, BMI-adjusted WHR or EA did not
 447 attenuate the IVW-MR effect estimates for causally associated metabolites when re-
 448 estimated (**Supplementary Table 15; Supplementary Material 3**). This suggests that
 449 the metabolite associations were not influenced by any correlation between the
 450 genetic instrument's effect and the effects of these traits as captured in the
 451 neuropsychiatric GWAS.

452

453 3.2.2 Metabolite prioritisation using MR-BMA

454 Prior to the per-outcome multivariate MR modelling in MR-BMA, we excluded the less
 455 statistically significant of any metabolite pair correlated $\geq 95\%$ (**Supplementary Table**
 456 **15**). As such, we excluded 5-methylthioadenosine (mta) from the AD model due to its
 457 correlation with the glucose to sucrose ratio, 5-dodecenoate (12:1n7) from the MS

458 model due to its correlation with N-formylmethionine and uridine, 2-myristoyl-GPC
459 (14:0)* from the ALS model due to its correlation with 1-stearoyl-GPC (O-18:0)* and the
460 glutamine to alanine ratio from the DEP model due to its correlation with gamma-
461 glutamylglutamine.

462 For AD, anxiety, MS, PD and schizophrenia, all metabolites had MIPs ≥ 0.1 ,
463 suggesting unique causal contributions to risk. For bipolar disorder, sphingosine 1-
464 phosphate, the ratio of histidine to phosphate and the ratio of glycine to pyridoxal
465 passed the MIP threshold, with 3-hydroxy-5-cholestenoic acid just under (MIP =
466 0.098). However, of the 12 metabolites included for depression, only the two
467 sphingomyelins (d18:1/24:1, d18:2/24:0 and d18:2/23:0, d18:1/23:1, d17:1/24:1) and
468 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) passed. For ALS, only
469 acetylcarnitine passed the MIP threshold. Acetylcarnitine had the highest overall MIP
470 of all metabolites tested (MIP = 0.893) (**Supplementary Table 16**).

471

472 3.2.3 Polygenic score (PGS) analysis

473 No MR-BMA prioritised metabolite PGS was associated with any of their respective
474 outcomes after FDR correction for 23 tests ($p_{FDR} \geq 0.05$). Nominal associations were
475 observed between depression and the PGS for sphingomyelin (d18:2/23:0,
476 d18:1/23:1, d17:1/24:1) and 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)
477 with identical effect sizes (OR[95%CI] = 0.989 [0.979-0.998], p -value range = 2.131
478 $\times 10^{-2}$ - 2.517×10^{-2}) and between the PGS for leucine and PD (OR [95%CI] = 0.962
479 [0.93- 0.996, p -value = 2.814×10^{-2}). These effects were directionally consistent with
480 the MR estimates but had non-relevant predictive ability given small Nagelkerke's
481 pseudo- r^2 estimates (Nagelkerke's pseudo- $r^2_{MAX} = 1.445 \times 10^{-4}$) (**Supplementary**
482 **Table 17**).

483

484 3.3 Further analysis of single instrument metabolites

485 3.3.1 Colocalisation at loci of influential instruments

486 Of the 44 colocalisation tests conducted in regions +/- 250 kb of the LOO influential
487 variants, 26 showed evidence of colocalisation (PP.H₄ ≥ 0.8) and a further five had
488 suggestive evidence (PP.H₄ ≥ 0.6) (**Supplementary Table 18**). All except one of these
489 regions were on chromosome 11 within a ~500_kb window (61293499-61854782 bp).
490 All disorders colocalising with metabolites in this region were psychiatric and every
491 psychiatric disorder examined showed colocalisation with at least one metabolite.
492 Colocalisation has been previously observed between the omega-3 fatty acid
493 docosahexaenoic acid (DHA) and depression within the same region³⁹.

494 All implicated metabolites except 1-stearoyl-2-docosapentaenoyl-GPC
495 (18:0/22:5n6)* were complex fatty acid chains containing the fatty acids arachidonic

496 acid (AA) ($N = 18$), linoleic acid (LA) ($N = 5$), alpha-linolenic acid (ALA) ($N = 1$) or
497 both AA and LA ($N = 4$). Higher levels of AA-containing metabolites were consistently
498 protective in Wald estimates while higher levels of LA- or ALA-containing metabolites
499 had risk increasing effects. Where ratios contained both AA- and LA-containing
500 metabolites, higher levels of the AA relative to the LA was protective and higher LA
501 metabolites relative to the AA risk increasing (**Supplementary Table 19**). This is
502 concordant with previous metabolome-wide MR analysis of bipolar disorder⁴¹ and
503 observational analysis of depression⁹⁸. The other region of colocalisation was
504 identified on chromosome 12 (56615338-57115338) between the ratio of histidine-to-
505 glutamine and AD (PP.H₄ = 0.92).

506 Two tests showed evidence of two distinct causal variants at the tested locus
507 – the ratio of glucose to mannose and depression (chr2: 27480940-27980940; PP.H₃
508 = 0.92) and docosapentaenoate (n6 DPA; 22:5n6) and bipolar disorder (chr11:
509 61347212-61847212; PP.H₃ = 0.99). Suggestive evidence for two distinct causal
510 variants was also identified for butyrylglycine and depression (chr12:120925524-
511 121425524; PP.H₃ = 0.70), methylsuccinate and depression (chr12:120926083-
512 121426083; PP.H₃ = 0.63), and 5-methyluridine (ribothymidine) and MS
513 (Chr22:50687969-51187969; PP.H₃ = 0.63). PP.H₃ ≥ 0.6 in these regions suggests
514 that MR estimated effects arose from linkage disequilibrium, violating MRs horizontal
515 pleiotropy assumption. Remaining colocalisation tests were inconclusive.

516

517 3.3.2 eQTL colocalisation

518 In total, nine genes were identified within 10 kb of credible SNPs at colocalising loci
519 (**Supplementary Table 20**). For the colocalisation analyses at chr11:61293499-
520 61854782, eQTLs for *MIR611* or *MIR1908* were not available in the eQTLGen
521 summary statistics. As such, follow-up eQTL colocalisation in this region was
522 conducted only with *MYRF*, *TMEM258*, *FEN1*, *FADS2* and *FADS1*. For the region
523 chr12:56615338-57115338, eQTLs were not available for *MIP*, but were available for
524 *GLS2* and *SPRYD4*. In total, 130 colocalisation tests were conducted with eQTLs. Of
525 these, only eQTLs for *SPRYD4* colocalised with both a risk metabolite and its
526 respective neuropsychiatric outcome: the ratio of histidine-to-glutamine (PP.H₄ =
527 0.91) and AD (PP.H₄ = 0.91). Additional colocalisation was identified for *GLS2* with
528 the ratio of histidine-to-glutamine (PP.H₄ = 0.99), but not AD (PP.H₄ = 0.42). *TMEM258*
529 colocalised with depression (PP.H₄ = 0.86). Suggestive colocalisation was identified
530 between *TMEM258* and anxiety and between *MYRF* and depression (PP.H₄ ≥ 0.6). Of
531 the remaining tests, 113 indicated two distinct causal variants in the region (PP.H₃ ≥
532 0.8), four were suggestive of only a causal variant for gene expression, and the
533 remainder inconclusive (**Supplementary Table 21**).

534

535 3.3.3 eQTL MR for the histidine to glutamine ratio and AD

536 We conducted MR analyses for the effect of *SPRYD4* expression levels on the ratio
537 of histidine-to-glutamine and AD using five independent instruments. *SPRYD4*
538 expression levels were identified as increasing risk for AD (OR = 1.08 [1.02-1.16], β
539 [95%CI] = 0.08 [0.02-0.15], p -value = 0.007) and the level of the ratio of histidine to
540 glutamine (β [95%CI] = 0.30 [0.18-0.42], p -value = 1.16×10^{-6}). SMR estimates for
541 the effect of *SPRYD4* expression were directionally consistent and statistically
542 significant at $p \leq 0.05$ for AD and the ratio of histidine-to-glutamine across eQTL
543 panels. HEIDI tests did not indicate heterogeneity ($p_{HEIDI} \geq 0.05$) (**Supplementary**
544 **Table 22**). There was no evidence that the ratio of histidine to glutamine substantially
545 mediates the effect of *SPRD4* expression on AD, with only a nominally significant
546 association and wide confidence intervals (proportion mediated [95%CI] = 63.20%
547 [1.80-124.59%], p -value = 0.043).


548

549 3.6 Further examination of histidine, glutamine, AD and *SPRYD4*

550 To further evaluate the association between the ratio of histidine to glutamine, we re-
551 examined the IVW-MR estimates for the separate effects of histidine and glutamine
552 on AD. No causal effect was observed for histidine on AD, not even nominally (OR =
553 1.11 [0.99-1.27], β = 0.11 [-0.011-0.24], p -value = 0.07). However, there was a
554 nominally significant negative causal effect for glutamine (OR = 0.87 [0.81-0.94], β
555 [95%CI] = -0.14 [-0.21 to -0.06], p -value = 0.0007, p_{FDR} = 0.052). Although glutamine
556 passed post-hoc sensitivity criteria with no evidence of pleiotropy or heterogeneity
557 (**Supplementary Table 23**), LOO identified the same influential variant on
558 chromosome 12 as observed for the ratio of histidine-to-glutamine – the 3'-UTR
559 variant rs2657879 (**Supplementary Table 24**). For glutamine, the effect of rs2657879
560 was in the opposite direction to the histidine-to-glutamine ratio.

561 A Wald ratio test using only this instrument estimated a negative effect of
562 glutamine on AD risk (OR = 0.84 [0.76-0.91], β = -0.19 [-0.28 to -0.09], p -value = 9.65
563 $\times 10^{-5}$). Strong evidence of colocalisation was observed between glutamine and AD
564 in the region (PP.H₄ = 0.92), and between glutamine and *SPRYD4* (PP.H₄ = 0.98)
565 (**Supplementary Table 25**). Gene expression levels of *SPRYD4* were negatively
566 associated with glutamine in the MR analysis (β = -0.35 [-0.52 to -0.18], p -value =
567 3.94×10^{-5}). Strong, directionally consistent effects of *SPRD4* expression on glutamine
568 were observed in SMR (**Supplementary Table 26**). However, the HEIDI tests
569 indicated heterogeneity ($p_{HEIDI} \leq 0.05$). There was no evidence that glutamine
570 mediated the effects of *SPRD4* expression on AD (proportion mediated [95%CI] =

571 75.81% [-0.36-151.99%], p -value = 0.051). LocusZoom plots for the ratio of histidine
 572 to glutamine, glutamine, AD and *SPRYD4* gene expression are shown in Figure 4.
 573



574 Figure 4: LocusZoom plots of the colocalising region ($PPH_4 \geq 0.8$) chr12: 56615338-57115338 for
 575 Alzheimer's disease, the ratio of histidine to glutamine, glutamine, and *SPRYD4* expression.

576 4. Discussion

577 We identified 77 unique plasma metabolites and a total of 85 sensitivity robust MR
578 estimated causal effects on neuropsychiatric disorder risk. Over half of associations
579 were driven by single influential variants. Of these, 30 metabolite-neuropsychiatric
580 disorder trait-pairs had greater than suggestive colocalisation and 29 were lipids
581 colocalising with a psychiatric disorder near the *FADS* gene cluster on chromosome
582 11. No eQTL colocalisation was observed for any metabolite-outcome trait-pair in this
583 region, suggesting the underlying mechanisms are not related to shared gene
584 expression effects. Additional colocalisation was observed between AD glutamine-
585 related metabolites and *SPRYD4* gene expression on chromosome 12. For the
586 remaining 41 polygenic metabolites, multivariate analysis with MR-BMA prioritised 23
587 metabolites and implicated sphingolipids and carnitine derivatives in psychiatric and
588 neurodegenerative risk respectively. However, the predictive performance of
589 metabolite polygenic scores was negligible in the UK Biobank.

590 Lipids – specifically polyunsaturated fatty acids (PUFAs) – have previously
591 shown MR causal effects on depression, with docosahexaenoic acid (DHA)
592 colocalising at the *FADS* gene cluster³⁹. Our study highlights the broader significance
593 of this region in linking lipid levels to risk across the psychiatric disorder spectrum.
594 Here, we identify suggestive colocalisation between at least one lipid and every
595 examined psychiatric disorder. Nearly all lipids colocalising with psychiatric
596 disorders contained linoleic acid (LA) or arachidonic acid (AA) – both omega-6
597 PUFAs. AA-containing lipids were consistently protective, while LA-containing lipids
598 increased risk. These findings are consistent with other MR studies of bipolar
599 disorder, depression and schizophrenia^{41,99,100}. Our results suggest that these
600 associations extend to ANX. Although these effects were primarily driven by shared
601 causal variants on chromosome 11, several polygenic metabolites comprised of
602 AA/LA-containing lipids also showed causal effect on psychiatric risk. The ratio of
603 arachidonate (20:4n6)-to-oleate-to-vaccenate (18:1) and 1-(1-enyl-palmitoyl)-2-
604 arachidonoyl-GPC (P-16:0/20:4) – both AA-containing – had risk decreasing effects
605 on anxiety and depression respectively and were prioritised in multivariate analysis.
606 In single instrument analyses, this ratio had risk decreasing effects on bipolar
607 disorder, depression and schizophrenia, colocalising with all. These results suggest
608 that effects of AA/LA-containing lipids in psychiatric risk may extend beyond effects
609 on chromosome 11.

610 Circulating levels of lipids containing LA and AA may be promising intervention
611 targets for psychiatric disorders. LA – the most abundant omega-6 PUFA in the
612 western diet – is found in nearly all manufactured food through vegetable oils¹⁰¹, while
613 AA is found in animal products such as meat, poultry, fish and eggs¹⁰². As free fatty

614 acids AA is a downstream product of LA, from which it is synthesised through
615 desaturation and chain elongation¹⁰² (**Supplementary Material 4**).

616 Free LA and AA are linked to inflammatory dysregulation¹⁰³ – itself implicated
617 in psychiatric disorders^{104,105}. AA is catalysed by cytochrome P450 enzymes to
618 epoxyeicosatrienoic acids (EETs), which show anti-inflammatory effects and are
619 suggested to be protective of neurological function¹⁰⁶. The deleterious effects of LA-
620 containing lipids compared to the protective effects of AA-containing lipids may
621 implicate dysregulated conversion from LAs to AAs, contributing to elevated
622 inflammation as less AA is available for conversion to anti-inflammatory EETs.
623 However, LA-to-AA conversion is relatively low in humans and requires LA to be in
624 free form following cleavage from lipid molecules via enzymes such as
625 phospholipase A2 (PLA2). Although PLA2 action on fatty acids has been previously
626 linked to inflammatory depression¹⁰⁷, further investigation is required to elucidate
627 mechanisms by which LA- and AA-containing lipids contribute to psychiatric risk.

628 The effects of the ratio of histidine-to-glutamine and glutamine on AD observed
629 here are in line with previous MR evidence suggesting higher blood glutamine as
630 protective^{37,108}. Interestingly, glutamine is noted to exert a neuroprotective effect
631 against β -amyloid aggregation¹⁰⁹ – a key drug target for AD¹¹⁰. This study provides
632 further evidence for its protective effects on AD risk and suggests the association is
633 driven by shared causal variants on chromosome 12. Further, we observe that the
634 association between AD and glutamine may be partially driven by the mutual effect
635 of *SPRYD4* gene expression. As *SPRYD4* has not been previously identified in AD
636 GWAS it represents a novel locus of interest for future study.

637 Our study also provides further evidence for the role of sphingolipid
638 metabolism in psychiatric disorders. Sphingolipids are fatty acids with roles in cell
639 growth/death, inflammation, mitochondrial function and immune response¹¹¹. We
640 identified two sphingomyelins and glycosyl-N-stearoyl-sphingosine (d18:1/18:0) as
641 protective for depression, with the sphingomyelins both prioritised in multivariate
642 analysis. Further, sphingomyelin (d18:1/18:1, d18:2/18:0) was protective for
643 schizophrenia and sphingosine-1-phosphate indicated to elevate risk of bipolar
644 disorder. Sphingomyelins are central to ceramide metabolism, to which they are
645 converted via sphingomyelinase and back via sphingomyelin synthase¹¹²
646 (**Supplementary Material 5**). Ceramides are catabolised into sphingosine and
647 eventually sphingosine-1-phosphate¹¹². General dysfunction of sphingolipid
648 metabolism, particularly ceramide aggregation, has been previously observed in
649 psychiatric disorders^{23,24,111,112} and reduced sphingomyelin levels may contribute to
650 elevated neuroinflammation¹¹². As such, the ceramide system is a proposed pathway
651 for drug-based interventions for psychiatric disorders¹¹². This study implicates
652 sphingomyelins as possible protective targets.

653 Although fewer metabolomic patterns were observed in neurodegenerative
654 disorders we did observe protective effects of several carnitine related metabolites –
655 adipoylcarnitine for MS and acetylcarnitine and propionylcarnitine for ALS. All three
656 are metabolised from L-carnitine, which plays a role in the transportation of fatty acids
657 to mitochondria¹¹³, and when acetylated is suggested to slow disease progression for
658 both disorders and AD^{114–116}. Further, lower serum carnitine levels are observed in
659 ALS¹¹⁷ and are associated with increased fatigue in MS¹¹⁸. A randomised control trial
660 (RCT) of acetylcarnitine supplementation in ALS suggests it may improve self-
661 sufficiency in patients compared to placebo¹¹⁴. The importance of acetylcarnitine for
662 ALS is further emphasised by our multivariate analysis, where it was the only
663 metabolite prioritised for ALS and had the highest MIP of any metabolite examined.
664 Interestingly, a larger phase two/three RCT of acetylcarnitine effects on biological and
665 clinical outcomes in ALS is underway
666 (<https://classic.clinicaltrials.gov/ct2/show/NCT06126315>). The remaining polygenic
667 metabolites did not show clear functional relatedness, indicating disorder-specific
668 metabolomic contributions – broadly confirmed in MR-BMA, where, for most
669 disorders, all metabolites had a MIP ≥ 0.1 , indicating unique causal effects.

670 Although no specific metabolites were identified with an effect on both a
671 psychiatric and neurodegenerative disorder, our results suggest the general
672 importance circulating lipids in both categories. Dietary lipids are known to modulate
673 neuroinflammation and play an important role in the brain by regulating neuronal and
674 synaptic function¹¹⁹. Future studies exploring biological overlap in neuropsychiatric
675 disorders may therefore wish to focus on lipidomic analysis for the purposes of further
676 elucidating shared metabolic pathways.

677 Several disorder-specific metabolites warrant further discussion. For example,
678 we replicated the risk-increasing effect of uridine on MS previously identified
679 observationally and in MR^{40,120}. Uridine is linked to pyrimidine metabolism with
680 important biological functions including RNA synthesis and the regulation of glucose,
681 lipid and amino acid levels¹²¹. Interesting, within pyrimidine biosynthesis, uridine is an
682 eventual metabolic product of dihydroorotate¹²¹, also identified here as increasing
683 risk for MS. Additionally, the branch chain amino acids (BCAAs) leucine and its
684 isomer isoleucine were both protective for PD. Plasma levels are noted to be lower in
685 cases than controls and correlated with increased functional disability¹²². In an RCT
686 of PD/parkinsonism, supplementation with leucine and vitamin D enriched whey
687 protein was significantly associated with increased lower body function and muscle
688 mass retention¹²³. Our findings provide further evidence of the protective effects of
689 leucine/isoleucine in PD and suggest them as possible interventional targets.

690 In the UKB, PGS for prioritised polygenic metabolites showed limited
691 prediction of their respective outcome disorder. Polygenic scores are noted to explain

692 only a small proportion of the variance even within the same phenotype¹²⁴. As such,
693 it is not entirely surprising that we are unable to detect significant associations cross-
694 trait, particularly given the smaller effective target sample size available in the UKB
695 compared to the large, meta-analytic samples sizes available from GWAS summary
696 statistics for use in MR. To improve prediction, future studies might aggregate the
697 genetic effects of multiple metabolites to better capture the total underlying metabolic
698 risk for disease, for example through a multi-PGS framework¹²⁵.

699 In conclusion, we performed metabolome-wide MR to test the causal effects
700 of 1300 metabolites/metabolite ratios on eight neuropsychiatric disorders. Results
701 implicate AA and LA-containing lipids across the psychiatric disorder spectrum, with
702 shared causal variants identified near the *FADS* gene cluster. We also identified
703 shared causal variants between glutamine metabolites and Alzheimer's disease, and
704 identify a shared effect of *SPRD4* gene expression. Additionally, our results implicate
705 sphingolipid metabolism in psychiatric disorders and carnitine related metabolites as
706 protective for MS and ALS, alongside several promising target metabolites with
707 disease-specific effects. More broadly, this study suggests that lipid metabolism
708 plays an important role in both psychiatric and neurodegenerative risk. The
709 metabolites identified in this study can help inform potential interventions and future,
710 targeted studies of metabolic contributions to disease risk.

711

712 5. Limitations

713 This study used data from individuals of European ancestry only and as such may
714 lack generalisability. Further, as previously noted⁷⁹, although the exclusion of the
715 *APOE* region from the AD analyses is necessary to avoid violating MR assumptions,
716 this may result in false negatives due to the regions known role in lipid metabolism¹²⁶.
717 Conversely, we can have greater confidence that the metabolites identified here are
718 not confounded by *APOE* effects. Given the importance of this region in AD and lipid
719 metabolism, it deserves specific focus in future metabolomic work. Further, MR
720 requires that several assumptions – such the availability of suitable instruments and
721 absence of pleiotropic effects – be met to provide reliable results. Although we
722 mitigate against these by including only strong instruments (F-statistic ≥ 10) and
723 using a robust sensitivity criterion to delineate causal metabolites, results should be
724 interpreted with caution prior to further triangulation.

725

726 6. Funding and acknowledgements

727 LG is funded by the King's College London DRIVE-Health Centre for Doctoral Training
728 and the Perron Institute for Neurological and Translational. JM is supported by the
729 King's Prize Fellowship. This study has been partly delivered through the National

730 Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre
731 (BRC). PP is funded by an Alzheimer's Research UK Senior Research Fellowship.

732 This research has been conducted using the UK Biobank Resource under
733 Application Number 82877. Ethical approval for the UK Biobank study has been
734 granted by the National Information Governance Board for Health and Social Care
735 and the NHS North West Multicentre Research Ethics Committee (11/NW/0382).
736 Written informed consent was obtained from all participants by the UK Biobank. We
737 thank the UK Biobank Team for collecting the data and making it available. We also
738 thank the UK Biobank participants.

739 We also thank and acknowledge the contribution and use of the CREATE high-
740 performance computing cluster at King's College London (King's College London.
741 (2022). King's Computational Research, Engineering and Technology Environment
742 (CREATE)).

743 We want to acknowledge the participants of the FinnGen study and the
744 veterans of the Million Veterans Project, as well as the research teams for both
745 studies.

746 For the purposes of open access, the author has applied a Creative Commons
747 Attribution (CC BY) license to any Accepted Author Manuscript version arising from
748 this submission.

749

750 **7. Data availability**

751 Data is available on reasonable request from the UK Biobank
752 (<https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/contact-us>).

753 Summary statistics from FinnGen are available online
754 (https://www.finnngen.fi/en/access_results) and from the Million Veterans Project via
755 dbGaP request ([https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
756 bin/study.cgi?studyid=phs001672.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?studyid=phs001672.v1.p1)).

757 GWAS summary statistics from the Psychiatric Genomics Consortium (PGC)
758 for Alzheimer's disease, anxiety, bipolar disorder, depression and schizophrenia are
759 available from their website (<https://pgc.unc.edu/for-researchers/download-results/>).

760 Summary statistics for anxiety from iPSYCH are also available online
761 (<https://ipsych.dk/en/research/downloads>). For Parkinson's disease and ALS,

762 summary statistics are available on GWAS Catalog at
763 <https://www.ebi.ac.uk/gwas/studies/GCST009325> and

764 <https://www.ebi.ac.uk/gwas/studies/GCST90027164> respectively. For multiple

765 sclerosis, summary statistics are available through the IEU Open GWAS Project
766 (<https://gwas.mrcieu.ac.uk/datasets/ieu-b-18/>). Summary statistics for metabolites

767 measured from Chen et al.⁵⁸ are available on GWAS catalog

768 (<https://www.ebi.ac.uk/gwas/studies/>) under accession numbers GCST90199621-
769 90201020. Access to summary statistics for the metabolites measured by Hysi et al.⁵⁹
770 were made available following request to the original authors.

771

772 **8. Conflicts of Interest**

773 CML is on the Scientific Advisory Board of Myriad Neuroscience and has received
774 honoraria for consultancy from UCB. C.L.-Q. has received consultancy fees from
775 Pfizer. C.L.-Q. has received honoraria, travel or speakers' fees from Biogen and
776 research funds from Pfizer and Novo Nordisk. C.L.-Q. is the director of the company
777 BrainLogia. All other authors declare no competing interests.

778 References

779

- 780 1. Plana-Ripoll, O. *et al.* Exploring comorbidity within mental disorders among a danish
781 national population. *JAMA Psychiatry* **76**, 259–270 (2019).
- 782 2. Grotzinger, A. D. *et al.* Genetic architecture of 11 major psychiatric disorders at
783 biobehavioral, functional genomic and molecular genetic levels of analysis. *Nat. Genet.*
784 **54**, 548–559 (2022).
- 785 3. Aarsland, D. *et al.* Neuropsychiatric symptoms in patients with Parkinson’s disease and
786 dementia: frequency, profile and associated care giver stress. *J. Neurol. Neurosurg.*
787 *Psychiatry* **78**, 36–42 (2007).
- 788 4. Turner, M. R., Goldacre, R., Talbot, K. & Goldacre, M. J. Psychiatric disorders prior to
789 amyotrophic lateral sclerosis. *Ann. Neurol.* **80**, 935–938 (2016).
- 790 5. Ismail, Z. *et al.* Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic
791 opportunities. *Nat. Rev. Neurol.* **18**, 131–144 (2022).
- 792 6. Chertcoff, A. S. *et al.* Psychiatric comorbidity during the prodromal period in patients
793 with multiple sclerosis. *Neurology* **101**, e2026–e2034 (2023).
- 794 7. Burchill, E. *et al.* The impact of psychiatric comorbidity on Parkinson’s disease
795 outcomes: a systematic review and meta-analysis. *Lancet Reg. Health Eur.* **39**, 100870
796 (2024).
- 797 8. Wainberg, M., Andrews, S. J. & Tripathy, S. J. Shared genetic risk loci between
798 Alzheimer’s disease and related dementias, Parkinson’s disease, and amyotrophic
799 lateral sclerosis. *Alzheimers Res. Ther.* **15**, 113 (2023).
- 800 9. Wightman, D. P. *et al.* The genetic overlap between Alzheimer’s disease, amyotrophic
801 lateral sclerosis, Lewy body dementia, and Parkinson’s disease. *Neurobiol. Aging* **127**,
802 99–112 (2023).
- 803 10. Gimson, A., Schlosser, M., Huntley, J. D. & Marchant, N. L. Support for midlife
804 anxiety diagnosis as an independent risk factor for dementia: a systematic review. *BMJ*
805 *Open* **8**, e019399 (2018).
- 806 11. Kuusimäki, T. *et al.* Increased risk of parkinson’s disease in patients with schizophrenia
807 spectrum disorders. *Mov. Disord.* **36**, 1353–1361 (2021).
- 808 12. Richmond-Rakerd, L. S., D’Souza, S., Milne, B. J., Caspi, A. & Moffitt, T. E.
809 Longitudinal Associations of Mental Disorders With Dementia: 30-Year Analysis of
810 1.7 Million New Zealand Citizens. *JAMA Psychiatry* **79**, 333–340 (2022).
- 811 13. Andreassen, O. A. *et al.* Genetic pleiotropy between multiple sclerosis and
812 schizophrenia but not bipolar disorder: differential involvement of immune-related gene
813 loci. *Mol. Psychiatry* **20**, 207–214 (2015).
- 814 14. McLaughlin, R. L. *et al.* Genetic correlation between amyotrophic lateral sclerosis and
815 schizophrenia. *Nat. Commun.* **8**, 14774 (2017).
- 816 15. Reynolds, R. H. *et al.* Local genetic correlations exist among neurodegenerative and
817 neuropsychiatric diseases. *npj Parkinsons Disease* **9**, 70 (2023).
- 818 16. Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and
819 neurodegenerative diseases. *Nat. Commun.* **13**, 4314 (2022).
- 820 17. Harerimana, N. V. *et al.* Genetic evidence supporting a causal role of depression in
821 alzheimer’s disease. *Biol. Psychiatry* **92**, 25–33 (2022).
- 822 18. Patti, G. J., Yanes, O. & Siuzdak, G. Innovation: Metabolomics: the apogee of the
823 omics trilogy. *Nat. Rev. Mol. Cell Biol.* **13**, 263–269 (2012).
- 824 19. Guijas, C., Montenegro-Burke, J. R., Warth, B., Spilker, M. E. & Siuzdak, G.
825 Metabolomics activity screening for identifying metabolites that modulate phenotype.
826 *Nat. Biotechnol.* **36**, 316–320 (2018).

- 827 20. Garana, B. B. & Graham, N. A. Metabolomics paves the way for improved drug target
828 identification. *Mol. Syst. Biol.* **18**, e10914 (2022).
- 829 21. Rinschen, M. M., Ivanisevic, J., Giera, M. & Siuzdak, G. Identification of bioactive
830 metabolites using activity metabolomics. *Nat. Rev. Mol. Cell Biol.* **20**, 353–367 (2019).
- 831 22. Gowda, G. A. N. *et al.* Metabolomics-based methods for early disease diagnostics.
832 *Expert Rev Mol Diagn* **8**, 617–633 (2008).
- 833 23. Dinoff, A., Herrmann, N. & Lanctôt, K. L. Ceramides and depression: A systematic
834 review. *J. Affect. Disord.* **213**, 35–43 (2017).
- 835 24. Brunkhorst-Kanaan, N. *et al.* Targeted lipidomics reveal derangement of ceramides in
836 major depression and bipolar disorder. *Metab. Clin. Exp.* **95**, 65–76 (2019).
- 837 25. Filippatou, A. G. *et al.* Serum ceramide levels are altered in multiple sclerosis. *Mult.*
838 *Scler.* **27**, 1506–1519 (2021).
- 839 26. Chowdhury, M. R., Jin, H. K. & Bae, J.-S. Diverse roles of ceramide in the progression
840 and pathogenesis of alzheimer’s disease. *Biomedicines* **10**, (2022).
- 841 27. Vos, M., Klein, C. & Hicks, A. A. Role of ceramides and sphingolipids in parkinson’s
842 disease. *J. Mol. Biol.* **435**, 168000 (2023).
- 843 28. Davey Smith, G. & Ebrahim, S. Epidemiology--is it time to call it a day? *Int. J.*
844 *Epidemiol.* **30**, 1–11 (2001).
- 845 29. Webhofer, C. *et al.* Metabolite profiling of antidepressant drug action reveals novel
846 drug targets beyond monoamine elevation. *Transl. Psychiatry* **1**, e58 (2011).
- 847 30. Pillinger, T. *et al.* Comparative effects of 18 antipsychotics on metabolic function in
848 patients with schizophrenia, predictors of metabolic dysregulation, and association with
849 psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* **7**,
850 64–77 (2020).
- 851 31. Shao, Y. *et al.* Comprehensive metabolic profiling of Parkinson’s disease by liquid
852 chromatography-mass spectrometry. *Mol. Neurodegener.* **16**, 4 (2021).
- 853 32. Pu, J. *et al.* Effects of pharmacological treatment on metabolomic alterations in animal
854 models of depression. *Transl. Psychiatry* **12**, 175 (2022).
- 855 33. Murgia, F. *et al.* Metabolomic Changes in Patients Affected by Multiple Sclerosis and
856 Treated with Fingolimod. *Metabolites* **13**, (2023).
- 857 34. Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G.
858 Mendelian randomization: using genes as instruments for making causal inferences in
859 epidemiology. *Stat. Med.* **27**, 1133–1163 (2008).
- 860 35. Smith, G. D. & Ebrahim, S. “Mendelian randomization”: can genetic epidemiology
861 contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.*
862 **32**, 1–22 (2003).
- 863 36. Abdellaoui, A., Yengo, L., Verweij, K. J. H. & Visscher, P. M. 15 years of GWAS
864 discovery: Realizing the promise. *Am. J. Hum. Genet.* **110**, 179–194 (2023).
- 865 37. Lord, J. *et al.* Disentangling independent and mediated causal relationships between
866 blood metabolites, cognitive factors, and alzheimer’s disease. *Biological Psychiatry*
867 *Global Open Science* **2**, 167–179 (2022).
- 868 38. Zacharias, H. U. *et al.* A metabolome-wide association study in the general population
869 reveals decreased levels of serum laurycarnitine in people with depression. *Mol.*
870 *Psychiatry* **26**, 7372–7383 (2021).
- 871 39. Davyson, E. *et al.* Metabolomic investigation of major depressive disorder identifies a
872 potentially causal association with polyunsaturated fatty acids. *Biol. Psychiatry* **94**,
873 630–639 (2023).
- 874 40. Ge, A., Sun, Y., Kiker, T., Zhou, Y. & Ye, K. A metabolome-wide Mendelian
875 randomization study prioritizes potential causal circulating metabolites for multiple
876 sclerosis. *J. Neuroimmunol.* **379**, 578105 (2023).

- 877 41. Stacey, D., Benyamin, B., Lee, S. H. & Hyppönen, E. A Metabolome-Wide Mendelian
878 Randomization Study Identifies Dysregulated Arachidonic Acid Synthesis as a
879 Potential Causal Risk Factor for Bipolar Disorder. *Biol. Psychiatry* (2024).
880 doi:10.1016/j.biopsych.2024.02.1005
- 881 42. Purves, K. L. *et al.* A major role for common genetic variation in anxiety disorders.
882 *Mol. Psychiatry* **25**, 3292–3303 (2020).
- 883 43. Meier, S. M. *et al.* Genetic Variants Associated With Anxiety and Stress-Related
884 Disorders: A Genome-Wide Association Study and Mouse-Model Study. *JAMA*
885 *Psychiatry* (2019). doi:10.1001/jamapsychiatry.2019.1119
- 886 44. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
887 population. *Nature* **613**, 508–518 (2023).
- 888 45. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder
889 cases provides new insights into the underlying biology. *Nat. Genet.* **53**, 817–829
890 (2021).
- 891 46. Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102
892 independent variants and highlights the importance of the prefrontal brain regions. *Nat.*
893 *Neurosci.* **22**, 343–352 (2019).
- 894 47. Levey, D. F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and
895 meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat.*
896 *Neurosci.* **24**, 954–963 (2021).
- 897 48. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
898 schizophrenia. *Nature* **604**, 502–508 (2022).
- 899 49. van Rheenen, W. *et al.* Common and rare variant association analyses in amyotrophic
900 lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-
901 specific biology. *Nat. Genet.* **53**, 1636–1648 (2021).
- 902 50. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map
903 implicates peripheral immune cells and microglia in susceptibility. *Science* **365**, (2019).
- 904 51. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for
905 Parkinson’s disease: a meta-analysis of genome-wide association studies. *Lancet*
906 *Neurol.* **18**, 1091–1102 (2019).
- 907 52. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
908 genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 909 53. Liu, H. *et al.* Mendelian randomization highlights significant difference and genetic
910 heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy
911 phenotype GWAX. *Alzheimers Res. Ther.* **14**, 17 (2022).
- 912 54. Lumsden, A. L., Mulugeta, A., Zhou, A. & Hyppönen, E. Apolipoprotein E (APOE)
913 genotype-associated disease risks: a phenome-wide, registry-based, case-control study
914 utilising the UK Biobank. *EBioMedicine* **59**, 102954 (2020).
- 915 55. Bulik-Sullivan, B. *et al.* LD Score regression distinguishes confounding from
916 polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 917 56. Grotzinger, A. D. *et al.* Genomic structural equation modelling provides insights into
918 the multivariate genetic architecture of complex traits. *Nat. Hum. Behav.* **3**, 513–525
919 (2019).
- 920 57. Grotzinger, A. D., Fuente, J. de la, Privé, F., Nivard, M. G. & Tucker-Drob, E. M.
921 Pervasive Downward Bias in Estimates of Liability-Scale Heritability in Genome-wide
922 Association Study Meta-analysis: A Simple Solution. *Biol. Psychiatry* **93**, 29–36
923 (2023).
- 924 58. Chen, Y. *et al.* Genomic atlas of the plasma metabolome prioritizes metabolites
925 implicated in human diseases. *Nat. Genet.* **55**, 44–53 (2023).
- 926 59. Hysi, P. G. *et al.* Metabolome Genome-Wide Association Study Identifies 74 Novel

- 927 Genomic Regions Influencing Plasma Metabolites Levels. *Metabolites* **12**, (2022).
- 928 60. Murphy, A. E., Schilder, B. M. & Skene, N. G. MungeSumstats: A Bioconductor
929 package for the standardisation and quality control of many GWAS summary statistics.
930 *Bioinformatics* (2021). doi:10.1093/bioinformatics/btab665
- 931 61. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and
932 richer datasets. *Gigascience* **4**, s13742–015–0047–8 (2015).
- 933 62. 1000 Genomes Project Consortium *et al.* A global reference for human genetic
934 variation. *Nature* **526**, 68–74 (2015).
- 935 63. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. *BioRxiv* (2020).
936 doi:10.1101/2020.08.10.244293
- 937 64. Palmos, A. B. *et al.* Proteome-wide Mendelian randomization identifies causal links
938 between blood proteins and severe COVID-19. *PLoS Genet.* **18**, e1010042 (2022).
- 939 65. Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian
940 randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int. J.*
941 *Epidemiol.* **45**, 1961–1974 (2016).
- 942 66. Burgess, S. *et al.* Guidelines for performing Mendelian randomization investigations:
943 update for summer 2023. *Wellcome Open Res.* **4**, 186 (2019).
- 944 67. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and
945 powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B*
946 *(Methodological)* **57**, 289–300 (1995).
- 947 68. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
948 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
949 Estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).
- 950 69. Burgess, S., Bowden, J., Dudbridge, F. & Thompson, S. G. Robust instrumental
951 variable methods using multiple candidate instruments with application to Mendelian
952 randomization. *arXiv* (2016). doi:10.48550/arxiv.1606.03729
- 953 70. Xue, H., Shen, X. & Pan, W. Constrained maximum likelihood-based Mendelian
954 randomization robust to both correlated and uncorrelated pleiotropic effects. *Am. J.*
955 *Hum. Genet.* **108**, 1251–1269 (2021).
- 956 71. Burgess, S., Foley, C. N., Allara, E., Staley, J. R. & Howson, J. M. M. A robust and
957 efficient method for Mendelian randomization with hundreds of genetic variants. *Nat.*
958 *Commun.* **11**, 376 (2020).
- 959 72. Rees, J. M. B., Wood, A. M., Dudbridge, F. & Burgess, S. Robust methods in
960 Mendelian randomization via penalization of heterogeneous causal estimates. *PLoS*
961 *One* **14**, e0222362 (2019).
- 962 73. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
963 instruments: effect estimation and bias detection through Egger regression. *Int. J.*
964 *Epidemiol.* **44**, 512–525 (2015).
- 965 74. Zhu, Z. *et al.* Causal associations between risk factors and common diseases inferred
966 from GWAS summary data. *Nat. Commun.* **9**, 224 (2018).
- 967 75. Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body
968 mass index in ~700000 individuals of European ancestry. *Hum. Mol. Genet.* **27**, 3641–
969 3649 (2018).
- 970 76. Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat
971 distribution in 694 649 individuals of European ancestry. *Hum. Mol. Genet.* **28**, 166–
972 174 (2019).
- 973 77. Okbay, A. *et al.* Polygenic prediction of educational attainment within and between
974 families from genome-wide association analyses in 3 million individuals. *Nat. Genet.*
975 **54**, 437–449 (2022).
- 976 78. Zuber, V., Colijn, J. M., Klaver, C. & Burgess, S. Selecting likely causal risk factors

- 977 from high-throughput experiments using multivariable Mendelian randomization. *Nat.*
978 *Commun.* **11**, 29 (2020).
- 979 79. Lord, J. *et al.* Mendelian randomization identifies blood metabolites previously linked
980 to midlife cognition as causal candidates in Alzheimer’s disease. *Proc. Natl. Acad. Sci.*
981 *USA* **118**, (2021).
- 982 80. Vilhjálmsón, B. J. *et al.* Modeling linkage disequilibrium increases accuracy of
983 polygenic risk scores. *Am. J. Hum. Genet.* **97**, 576–592 (2015).
- 984 81. Choi, S. W., Mak, T. S.-H. & O’Reilly, P. F. Tutorial: a guide to performing polygenic
985 risk score analyses. *Nat. Protoc.* **15**, 2759–2772 (2020).
- 986 82. Pain, O., Al-Chalabi, A. & Lewis, C. M. The genopred pipeline: A comprehensive and
987 scalable pipeline for polygenic scoring. *medRxiv* (2024).
988 doi:10.1101/2024.06.12.24308843
- 989 83. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
990 *Nature* **562**, 203–209 (2018).
- 991 84. Zhang, Q., Privé, F., Vilhjálmsón, B. & Speed, D. Improved genetic prediction of
992 complex traits from individual-level data or summary statistics. *Nat. Commun.* **12**, 4192
993 (2021).
- 994 85. Ni, G. *et al.* A comparison of ten polygenic score methods for psychiatric disorders
995 applied across multiple cohorts. *Biol. Psychiatry* **90**, 611–620 (2021).
- 996 86. Monti, R. *et al.* Evaluation of polygenic scoring methods in five biobanks shows larger
997 variation between biobanks than methods and finds benefits of ensemble learning. *Am.*
998 *J. Hum. Genet.* **111**, 1431–1447 (2024).
- 999 87. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association
1000 studies. *Bioinformatics* **26**, 2867–2873 (2010).
- 1001 88. Spargo, T. P. *et al.* Statistical examination of shared loci in neuropsychiatric diseases
1002 using genome-wide association study summary statistics. (2023).
1003 doi:10.7554/eLife.88768
- 1004 89. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
1005 association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 1006 90. Vösa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic
1007 loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **53**, 1300–
1008 1310 (2021).
- 1009 91. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts
1010 complex trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
- 1011 92. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of
1012 known disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).
- 1013 93. Lloyd-Jones, L. R. *et al.* The genetic architecture of gene expression in peripheral
1014 blood. *Am. J. Hum. Genet.* **100**, 228–237 (2017).
- 1015 94. Auwerx, C. *et al.* Exploiting the mediating role of the metabolome to unravel transcript-
1016 to-phenotype associations. *Elife* **12**, (2023).
- 1017 95. Yoshiji, S. *et al.* Proteome-wide Mendelian randomization implicates nephronectin as
1018 an actionable mediator of the effect of obesity on COVID-19 severity. *Nat. Metab.* **5**,
1019 248–264 (2023).
- 1020 96. Koletzko, B. *et al.* FADS1 and FADS2 polymorphisms modulate fatty acid metabolism
1021 and dietary impact on health. *Annu. Rev. Nutr.* **39**, 21–44 (2019).
- 1022 97. Myers, T. A., Chanock, S. J. & Machiela, M. J. Ldlinkr: an R package for rapidly
1023 calculating linkage disequilibrium statistics in diverse populations. *Front. Genet.* **11**,
1024 157 (2020).
- 1025 98. Jansen, R. *et al.* The Metabolome-Wide Signature of Major Depressive Disorder. *Res.*
1026 *Sq.* (2023). doi:10.21203/rs.3.rs-3127544/v1

- 1027 99. Zeng, L. *et al.* Causal effects of fatty acids on depression: Mendelian randomization
1028 study. *Front. Nutr.* **9**, 1010476 (2022).
- 1029 100. Gao, Y. *et al.* Association between Arachidonic Acid and the Risk of Schizophrenia: A
1030 Cross-National Study and Mendelian Randomization Analysis. *Nutrients* **15**, (2023).
- 1031 101. Whelan, J. & Fritsche, K. Linoleic acid. *Adv. Nutr.* **4**, 311–312 (2013).
- 1032 102. Tallima, H. & El Ridi, R. Arachidonic acid: Physiological roles and potential health
1033 benefits - A review. *J. Advanc. Res.* **11**, 33–41 (2018).
- 1034 103. Innes, J. K. & Calder, P. C. Omega-6 fatty acids and inflammation. *Prostaglandins*
1035 *Leukot Essent Fatty Acids* **132**, 41–48 (2018).
- 1036 104. Yuan, N., Chen, Y., Xia, Y., Dai, J. & Liu, C. Inflammation-related biomarkers in
1037 major psychiatric disorders: a cross-disorder assessment of reproducibility and
1038 specificity in 43 meta-analyses. *Transl. Psychiatry* **9**, 233 (2019).
- 1039 105. Perry, B. I. *et al.* Associations of immunological proteins/traits with schizophrenia,
1040 major depression and bipolar disorder: A bi-directional two-sample mendelian
1041 randomization study. *Brain Behav. Immun.* **97**, 176–185 (2021).
- 1042 106. Wang, L., Luo, G., Zhang, L.-F. & Geng, H.-X. Neuroprotective effects of
1043 epoxyeicosatrienoic acids. *Prostaglandins Other Lipid Mediat* **138**, 9–14 (2018).
- 1044 107. Su, K.-P. *et al.* Phospholipase A2 and cyclooxygenase 2 genes influence the risk of
1045 interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels.
1046 *Biol. Psychiatry* **67**, 550–557 (2010).
- 1047 108. Adams, C. D. Circulating glutamine and alzheimer’s disease: A mendelian
1048 randomization study. *Clin Interv Aging* **15**, 185–193 (2020).
- 1049 109. Chen, J. & Herrup, K. Glutamine acts as a neuroprotectant against DNA damage, beta-
1050 amyloid and H2O2-induced stress. *PLoS One* **7**, e33177 (2012).
- 1051 110. Sims, J. R. *et al.* Donanemab in Early Symptomatic Alzheimer Disease: The
1052 TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA* **330**, 512–527 (2023).
- 1053 111. Bernal-Vega, S., García-Juárez, M. & Camacho-Morales, A. Contribution of ceramides
1054 metabolism in psychiatric disorders. *J. Neurochem.* **164**, 708–724 (2023).
- 1055 112. Zhuo, C. *et al.* Acid sphingomyelinase/ceramide system in schizophrenia: implications
1056 for therapeutic intervention as a potential novel target. *Transl. Psychiatry* **12**, 260
1057 (2022).
- 1058 113. Pekala, J. *et al.* L-carnitine--metabolic functions and meaning in humans life. *Curr*
1059 *Drug Metab* **12**, 667–678 (2011).
- 1060 114. Beghi, E. *et al.* Randomized double-blind placebo-controlled trial of acetyl-L-carnitine
1061 for ALS. *Amyotroph. Lateral Scler. Frontotemporal Degener.* **14**, 397–405 (2013).
- 1062 115. Pennisi, M. *et al.* Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A
1063 Critical Update. *Nutrients* **12**, (2020).
- 1064 116. Gharighnia, S., Omid, A., Ragerdi Kashani, I., Sepand, M. R. & Pour Beiranvand, S.
1065 Ameliorative effects of acetyl-L-carnitine on corpus callosum and functional recovery
1066 in demyelinated mouse model. *Int. J. Neurosci.* 1–11 (2022).
1067 doi:10.1080/00207454.2022.2107515
- 1068 117. Sarraf, P. *et al.* The correlation of the serum level of L-carnitine with disease severity in
1069 patients with Amyotrophic lateral sclerosis. *J. Clin. Neurosci.* **89**, 232–236 (2021).
- 1070 118. Harirchian, M. H., Babaie, S., Keshtkaran, N. & Bitarafan, S. The association of serum
1071 carnitine levels with severity of fatigue in patients with multiple sclerosis: A pilot
1072 study. *CJN* **22**, 30–34 (2023).
- 1073 119. Custers, Emma, E. M., Kiliaan & Amanda, J. Dietary lipids from body to brain. *Prog.*
1074 *Lipid Res.* **85**, 101144 (2022).
- 1075 120. Zahoor, I., Rui, B., Khan, J., Datta, I. & Giri, S. An emerging potential of metabolomics
1076 in multiple sclerosis: a comprehensive overview. *Cell Mol. Life Sci.* **78**, 3181–3203

- 1077 (2021).
1078 121. Zhang, Y., Guo, S., Xie, C. & Fang, J. Uridine metabolism and its role in glucose, lipid,
1079 and amino acid homeostasis. *Biomed Res. Int.* **2020**, 7091718 (2020).
1080 122. Zhang, Y. *et al.* Plasma branched-chain and aromatic amino acids correlate with the gut
1081 microbiota and severity of Parkinson's disease. *npj Parkinsons Disease* **8**, 48 (2022).
1082 123. Barichella, M. *et al.* Muscle-targeted nutritional support for rehabilitation in patients
1083 with parkinsonian syndrome. *Neurology* **93**, e485–e496 (2019).
1084 124. Lewis, C. M. & Vassos, E. Polygenic risk scores: from research tools to clinical
1085 instruments. *Genome Med.* **12**, 44 (2020).
1086 125. Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction by combining 937
1087 polygenic scores. *Nat. Commun.* **14**, 4702 (2023).
1088 126. Yang, L. G., March, Z. M., Stephenson, R. A. & Narayan, P. S. Apolipoprotein E in
1089 lipid metabolism and neurodegenerative disease. *Trends Endocrinol. Metab.* **34**, 430–
1090 445 (2023).
1091